Fig. 4From: The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney diseaseImpact of model inputs on incremental discounted costs, QALYs and NMB (WTP at £20,000 per QALY gained). CKD chronic kidney disease, CV cardiovascular event, NMB net monetary benefit, QALY quality-adjusted life-year, RAASi renin-angiotensin-aldosterone system inhibitor, RRT renal replacement therapy, WTP willingness-to-pay thresholdBack to article page